The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of <i>BCR/ABL in vitro</i> and in a xenograft model of chronic myeloid leukemia
Ignacio García‐Tuñón(Universidad de Salamanca), Manuel Sánchez‐Martín(Universidad de Salamanca)
Cited by 40